SCHEMBL20514264

SCHEMBL20514264

COc1cccc(OC)c1NC(=S)NNC(=O)c1cc(C)c(C)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 9/20 0.47
▸ SMN1; SMN2 Q16637 6/20 0.47
▸ ALDH1A1 P00352 6/20 0.47
▸ RAB9A P51151 5/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ HPGD P15428 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ IMPDH2 P12268 1/20 0.46
▸ MAPT P10636 2/20 0.45
▸ TP53 P04637 2/20 0.44
▸ MITF O75030 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ LMNA P02545 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ S1PR2 O95136 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20514287 0.83 HPGD (0.49) GAASMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL20514063 0.80 POLB (0.64) GAASMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL21961206 0.76 APLNR (0.36) GAASMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL20514204 0.76 GAA (0.64) GAASMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL20515252 0.74 POLB (0.43) GAASMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL20514022 0.73 GAA (0.51) GAASMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL20513984 0.72 ALDH1A1 (0.66) GAASMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL15484253 0.71 HPGD (0.51) GAASMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL20515255 0.70 GAA (0.73) GAASMN1; SMN2ALDH1A1HPGDPOLB
SCHEMBL20514246 0.69 POLB (0.51) SMN1; SMN2ALDH1A1HPGDPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12071413-B2 Azole derivatives as apelin receptor agonist Sanford Burnham Prebys Medical Discovery Institute (US) 2024-08-27 — — US disclosed
EP-3380970-B1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) 2023-01-04 — — EP disclosed
US-20220144784-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-05-12 — — US disclosed
US-20220144784-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-05-12 — — US disclosed
US-11155525-B2 Azole derivatives as apelin receptor agonist Sanford Burnham Prebys Medical Discovery Institute (US) 2021-10-26 — — US disclosed
US-11155525-B2 Azole derivatives as apelin receptor agonist Sanford Burnham Prebys Medical Discovery Institute (US) 2021-10-26 — — US disclosed
US-20200347022-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-11-05 — — US disclosed
US-20200347022-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-11-05 — — US disclosed
US-10626096-B2 Azole derivatives as apelin receptor agonist Sanford Burnham Prebys Medical Discovery Institute (US) 2020-04-21 — — US disclosed
US-10626096-B2 Azole derivatives as apelin receptor agonist Sanford Burnham Prebys Medical Discovery Institute (US) 2020-04-21 — — US disclosed
US-20180282289-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST DAIICHI SANKYO COMPANY, LIMITED (JP) 2018-10-04 — — US disclosed
EP-3380970-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST Sanford Burnham Prebys Medical Discovery Institute (US) 2018-10-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12071413-B2 Azole derivatives as apelin receptor agonist APLNR, AGTR1, AGTR2 GAA 4811/4885SMN1; SMN2 4614/4885ALDH1A1 2642/4885
US-11155525-B2 Azole derivatives as apelin receptor agonist APLNR, AGTR1, AGTR2 GAA 4811/4885SMN1; SMN2 4614/4885ALDH1A1 2642/4885
US-20200347022-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST APLNR, AGTR1, AGTR2 GAA 4828/4885SMN1; SMN2 4552/4885ALDH1A1 2968/4885
US-20220144784-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST APLNR, AGTR1, AGTR2 GAA 4811/4885SMN1; SMN2 4490/4885ALDH1A1 2845/4885
US-20180282289-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST APLNR, AGTR1, AGTR2 GAA 4811/4885SMN1; SMN2 4501/4885ALDH1A1 2828/4885
US-10626096-B2 Azole derivatives as apelin receptor agonist APLNR, AGTR1, AGTR2 GAA 4813/4885SMN1; SMN2 4618/4885ALDH1A1 2622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback